Antiviral innate immunity is diminished in the upper respiratory tract of severe COVID-19 patients
Abstract Understanding early innate immune responses to coronavirus disease 2019 (COVID–19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression leading to transcription of IFN-stimulated genes (ISGs) to control viral replication and spread. SARS-CoV-2 infection also elicits NF-κB signaling which regulates inflammatory cytokine expression contributing to viral control and likely disease severity. Few studies have simultaneously characterized these two components of innate immunity to COVID-19. We designed a study to characterize the expression of interferon alpha-2 (IFNA2) and interferon beta-1 (IFNB1), both type-1 interferons (IFN-1), interferongamma (IFNG), a type-2 interferon (IFN-2), ISGs, and NF-κB response genes in the upper respiratory tract (URT) of patients with mild (outpatient) versus severe (hospitalized) COVID-19. Further, we characterized the weekly dynamics of these responses in the upper and lower respiratory tracts (LRTs) and blood of severe patients to evaluate for compartmental differences. We observed significantly increased ISG and NF-κB responses in the URT of mild compared with severe patients early during illness. This pattern was associated with increasedIFNA2andIFNGexpression in the URT of mild patients, a trend toward increasedIFNB1-expression and significantly increasedSTING/IRF3/cGAS expression in the URT of severe patients. Our by-week across-compartment analysis in severe patients revealed significantly higher ISG responses in the blood compared with the URT and LRT of these patients during the first week of illness, despite significantly lower expression ofIFNA2, IFNB1, andIFNGin blood. NF-κB responses, however, were significantly elevated in the LRT compared with the URT and blood of severe patients during peak illness (week 2). Our data support that severe COVID-19 is associated with impaired interferon signaling in the URT during early illness and robust pro-inflammatory responses in the LRT during peak illness..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 30. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramos-Benitez, Marcos J. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.11.08.22281846 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037857894 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037857894 | ||
| 003 | DE-627 | ||
| 005 | 20231205091509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.11.08.22281846 |2 doi | |
| 035 | |a (DE-627)XBI037857894 | ||
| 035 | |a (biorXiv)10.1101/2022.11.08.22281846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramos-Benitez, Marcos J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiviral innate immunity is diminished in the upper respiratory tract of severe COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Understanding early innate immune responses to coronavirus disease 2019 (COVID–19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression leading to transcription of IFN-stimulated genes (ISGs) to control viral replication and spread. SARS-CoV-2 infection also elicits NF-κB signaling which regulates inflammatory cytokine expression contributing to viral control and likely disease severity. Few studies have simultaneously characterized these two components of innate immunity to COVID-19. We designed a study to characterize the expression of interferon alpha-2 (IFNA2) and interferon beta-1 (IFNB1), both type-1 interferons (IFN-1), interferongamma (IFNG), a type-2 interferon (IFN-2), ISGs, and NF-κB response genes in the upper respiratory tract (URT) of patients with mild (outpatient) versus severe (hospitalized) COVID-19. Further, we characterized the weekly dynamics of these responses in the upper and lower respiratory tracts (LRTs) and blood of severe patients to evaluate for compartmental differences. We observed significantly increased ISG and NF-κB responses in the URT of mild compared with severe patients early during illness. This pattern was associated with increasedIFNA2andIFNGexpression in the URT of mild patients, a trend toward increasedIFNB1-expression and significantly increasedSTING/IRF3/cGAS expression in the URT of severe patients. Our by-week across-compartment analysis in severe patients revealed significantly higher ISG responses in the blood compared with the URT and LRT of these patients during the first week of illness, despite significantly lower expression ofIFNA2, IFNB1, andIFNGin blood. NF-κB responses, however, were significantly elevated in the LRT compared with the URT and blood of severe patients during peak illness (week 2). Our data support that severe COVID-19 is associated with impaired interferon signaling in the URT during early illness and robust pro-inflammatory responses in the LRT during peak illness. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Strich, Jeffrey R. |4 aut | |
| 700 | 1 | |a Alehashemi, Sara |4 aut | |
| 700 | 1 | |a Stein, Sydney |4 aut | |
| 700 | 1 | |a Rastegar, Andre |4 aut | |
| 700 | 1 | |a de Jesus, Adriana Almeida |0 (orcid)0000-0001-8966-8362 |4 aut | |
| 700 | 1 | |a Bhuyan, Farzana |4 aut | |
| 700 | 1 | |a Ramelli, Sabrina |4 aut | |
| 700 | 1 | |a Babyak, Ashley |4 aut | |
| 700 | 1 | |a Perez-Valencia, Luis |4 aut | |
| 700 | 1 | |a Vannella, Kevin M. |4 aut | |
| 700 | 1 | |a Grubbs, Gabrielle |4 aut | |
| 700 | 1 | |a Khurana, Surender |4 aut | |
| 700 | 1 | |a Gross, Robin |4 aut | |
| 700 | 1 | |a Hadley, Kyra |4 aut | |
| 700 | 1 | |a Liang, Janie |4 aut | |
| 700 | 1 | |a Mazur, Steven |4 aut | |
| 700 | 1 | |a Postnikova, Elena |4 aut | |
| 700 | 1 | |a Warner, Seth |4 aut | |
| 700 | 1 | |a Holbrook, Michael R. |0 (orcid)0000-0002-0824-2667 |4 aut | |
| 700 | 1 | |a Busch, Lindsay M. |4 aut | |
| 700 | 1 | |a Warner, Blake |4 aut | |
| 700 | 1 | |a Applefeld, Willard |4 aut | |
| 700 | 1 | |a Warner, Sarah |4 aut | |
| 700 | 1 | |a Kadri, Sameer S |4 aut | |
| 700 | 1 | |a Davey, Richard T |4 aut | |
| 700 | 1 | |a Goldbach-Mansky, Raphaela |4 aut | |
| 700 | 1 | |a Chertow, Daniel S. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 30. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.11.08.22281846 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 30 |c 11 | ||